Mixed hepatocellular-cholangiocarcinomas (HCC-CCAs
exhibit pathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). (1) Most commonly, HCC-CCA tumors, thought to arise from hepatic progenitor cells, occur in the presence of preexisting abnormalities in parenchymal architecture, such as advanced fibrosis and cirrhosis associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. (2, 3) Unfortunately, accurate diagnosis of these tumors prior to initiation of therapies is difficult. In patients undergoing LT, approximately 0.7%-3.3% of tumors diagnosed as HCC via radiographic criteria or pathologic examination are later identified as HCC-CCA on evaluation of the explant pathology. (4) (5) (6) Because of the rarity of the tumors and difficulty in ORIGINAL ARTICLE | 1385 securing a definitive pretreatment diagnosis, determining the appropriate therapeutic intervention to optimize patient outcomes has been difficult.
For patients amenable to curative-intent surgical resection, recurrence rates are high and longterm survival poor, with only 20%-40% of patients alive at 5 years following surgery. (1, (7) (8) (9) In addition, the ability to offer liver resection for patients with HCC-CCA is frequently limited because of the presence of prohibitive underlying liver disease, leaving LT as the only potential curative option. A recent analysis of the United Network for Organ Sharing (UNOS) database identified 94 patients with HCC-CCA undergoing LT, who demonstrated significantly inferior overall survival of 40% at 5 years, compared with HCC recipients. (10) While UNOS and the Organ Procurement and Transplantation Network (OPTN) do not have an official policy with regard to LT for HCC-CCA, most members of the transplant community consider HCC-CCA a contraindication to LT because of the poor outcomes that have been observed in registry studies and single-center analyses. (5, 6, 8, (10) (11) (12) Thus, while posttransplant outcomes for patients with HCC-CCA, taken in aggregate, are inferior in comparison to all-comers with HCC, what is less clear is whether this is due to HCC-CCA demonstrating inherently more aggressive tumor behavior. In this current study, we sought to evaluate our experience with LT for HCC-CCA and compare their outcomes with 2 separate groups of propensity-matched HCC patients based on either pretransplant radiographic features and serum alpha-fetoprotein (AFP), or explant pathologic characteristics. A detailed analysis of the pretransplant radiographic features, explant pathologic characteristics, recurrence, and survival of patients with HCC-CCA is reported, as well as comparative outcomes to a propensity-matched group of HCC patients. Finally, we sought to identify a subset of HCC-CCA patients who have acceptable outcomes following LT.
Patients and Methods

StuDY CoHoRt
Using a prospectively maintained transplant database, we performed a retrospective review of all adult patients (18 years of age and older) who underwent LT for malignancy at the University of California, Los Angeles (UCLA), from 1984 to 2015. Histologic analysis of the explanted recipient liver was reviewed on all patients where explanted tumor was identified. Patients identified as having mixed HCC-CCA, CCA with HCC features, or HCC with CCA features were chosen for the study population (HCC-CCA, n = 12). Recipients with intrahepatic CCA were excluded. The first occurrence of mixed HCC-CCA pathology occurred in 1994, and the most recent occurrence occurred in 2014. A total of 4 patients were transplanted in the pre-MELD era, and the remaining 8 patients were transplanted in the post-MELD era.
To evaluate whether outcomes for HCC-CCA recipients were inherently different from patients with HCC, 2 separate propensity-matched analyses were performed. HCC-CCA LT recipients were matched 1:3 with HCC patients who had undergone LT during the same time period utilizing a propensity match score, which was generated based on either (1) pretransplant tumor characteristics (serum AFP and radiologic tumor diameter) or (2) explant tumor characteristics (pathologic diameter, grade/differentiation, and vascular invasion). Control candidates were selected based on the top 3 matches for each case, with each control only utilized once, resulting in a matched control cohort of 36 unique cases for each comparison group (1:3 matching). The overall study design is shown in Fig. 1 . Although the era of transplant was not a variable considered during statistical propensity matching, the ratio of patients transplanted within the pre-and post-MELD era was similar. For HCC patients matched based on AFP and radiographic criteria, 11 were transplanted in the pre-MELD era (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) ) and 25 were transplanted in the post-MELD era (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) 
DAtA CoLLECtioN
LT recipient data were longitudinally collected and evaluated from the time of initial tumor diagnosis through the end of the evaluation period (December 31, 2015). Multiple recipient (age, sex, primary end-stage liver disease [ESLD] diagnosis, diabetes, hypertension, hyperlipidemia, coronary artery disease, smoking, renal failure, and cerebrovascular disease), donor, operative (donor age, sex, heart-beating cadaveric, non-heart-beating cadaveric, split graft, cold ischemia time, and warm ischemia time), and laboratory (AFP, neutrophil-to-lymphocyte ratio [NLR] , MELD score, and total cholesterol) variables were analyzed. Pretransplant tumor radiographic data (number of lesions, maximal tumor diameter, and cumulative tumor diameter) and locoregional treatment variables ( 
StAtiStiCAL ANALYSiS
Descriptive statistics were reported for HCC-CCA recipients in comparison to HCC recipients matched 1:3 based on pretransplant tumor characteristics or explant tumor characteristics. Categorical variables were compared using Fisher's exact test or the chisquare test, and continuous data were compared using the nonparametric Wilcoxon rank sum test. Patient and recurrence-free survival was computed with the Kaplan-Meier method using the log-rank test for comparison. A P < 0.05 was considered statistically significant. All analyses were performed using SPSS Statistics, version 22 (IBM Corporation, Armonk, NY).
Results
During the 30-year study period, 12 adult patients were identified with explant tumor pathology consistent with HCC-CCA (Fig. 2) . The median follow-up time was 27.9 months (11.4 months for patients who died and 54.5 months for patient who were alive at last follow-up). Recipients with HCC-CCA had a median age of 54.8 years, and 75% of recipients were male. At transplantation, recipients had a median laboratory MELD of 10 ( Table 1) .
CoMPARiSoN of HCC-CCA WitH HCC RECiPiENtS MAtCHED BASED oN PREtRANSPLANt tuMoR CHARACtERiStiCS
LT recipients with HCC-CCA were matched 1:3 with LT recipients with HCC who demonstrated similar pretransplant tumor characteristics based on immediate pretransplant AFP levels (median 11.5 mg/dL versus 10.4 mg/dL; P = 0.76) and cumulative radiologic tumor diameter (median 4.7 cm versus 4.0 cm; P = 0.36). There were no significant differences in recipient demographic, donor, or operative ORIGINAL ARTICLE | 1387 characteristics between the 2 groups (Table 1) , with the exception of fewer partial liver allografts (0% versus 39%; P = 0.02) and shorter cold ischemia time (355 minutes versus 502 minutes; P = 0.009) in recipients with HCC-CCA compared with HCC, respectively.
Of the 12 patients, 6 had digitized radiographic imaging available for review, compared with the detailed radiographic reports available for the remaining 6 patients. Of 7 lesions in these 6 patients, all demonstrated infiltrative margins and none were encapsulated. (13) A heterogeneous or mosaic pattern of enhancement was noted in 6/7 lesions (85.7%) with 3/7 (42.9%) lesions meeting OPTN 5 criteria, thus resulting in the mistaken diagnosis of HCC by imaging criteria alone (Fig. 3 ).
The pretransplant tumor characteristics of HCC-CCA and matched HCC are shown in Table 2 . Compared with HCC recipients, HCC-CCA patients were more likely to have undergone systemic chemotherapy prior to LT (25% versus 3%; P = 0.04) but were less likely to have received RFA (8% versus 39%; P = 0.047). There were no other significant differences in the immediate pre-LT AFP (on which they were matched), maximum pre-LT AFP, NLR, radiographic number of lesions, cumulative tumor diameter, tumor location, radiologic size criteria, or other locoregional treatment modalities. Similar numbers of patients demonstrated response to locoregional therapy, resulting in downstaging of disease to Milan criteria (17% for HCC-CCA versus 11% for HCC; P = 0.47). Similar numbers of patient also demonstrated radiologic evidence of disease progression on pretransplant imaging (25% for HCC-CCA versus 17% for HCC; P = 0.40). Pretransplant biopsies were performed in 33% of HCC-CCA recipients compared with 44% of HCC recipients. No tumors in the HCC-CCA group were identified as having mixed HCC-CCA features on initial pathologic review. The histologic grade of the tumors on preoperative biopsy was not significantly different between HCC-CCA recipients and recipients with HCC, with 2 of the 4 HCC-CCA patients graded as moderately differentiated on pre-LT biopsy proving to have poorly differentiated tumors on explant.
Explant pathologic tumor characteristics are shown in Table 3 . Compared with HCC patients matched based on pretransplant characteristics, HCC-CCA recipients were significantly more likely to have higher grade (G3+G4 58% versus 11%; P = 0.003) and more poorly differentiated tumors (58% versus 8%; P = 0.002), but had similar American Joint Committee on Cancer (AJCC) T stage (P = 0.19), maximum tumor diameter (5.2 cm versus 4.0 cm; P = 0.18), cumulative tumor diameter (7.1 cm versus 5.0 cm; P = 0.43), microvascular (50% versus 31%; P = 0.30) invasion, and macrovascular (8% versus 3%; P = 0.44) invasion. There were no differences in extent of tumor necrosis, multifocality, or pathologic Milan criteria among the groups.
Posttransplant incidence of cancer recurrence, overall survival, and recurrence-free survival is shown in Fig. 4 . Compared with HCC recipients with similar pretransplant characteristics, HCC-CCA patients had nonstatistically significant higher 1-, 3-, and 5-year recurrence rates (16%, 50%, and 50% versus 14%, 19%, and 22%; P = 0.07; Fig. 4A ), as well as a clear trend for inferior 1-, 3-, and 5-year overall survival (75%, 54%, and 42% versus 88%, 68%, and 65%; P = 0.13; Fig. 4B ) and recurrence-free survival (66%, 42%, and 42% versus 76%, 67%, and 61%; P = 0.17; Fig. 4C ).
CoMPARiSoN of HCC-CCA WitH HCC RECiPiENtS MAtCHED BASED oN EXPLANt PAtHoLoGiC CHARACtERiStiCS
While HCC-CCA recipients with similar pretransplant characteristics (radiologic and immediate pre-LT AFP) were more likely to have the worst pathologic features, we next sought to match HCC-CCA recipients with HCC patients with similar pathologic characteristics in order to evaluate whether HCC-CCA tumors were inherently more aggressive when controlling for pathologic characteristics. Thus, a second propensity matching was performed, with HCC-CCA patients matched 1:3 to HCC LT recipients based on explant pathologic tumor diameter (7.1 cm versus 8.5 cm; P = 0.35), tumor differentiation (25% well-differentiated, 17% moderately differentiated, and 58% poorly differentiated for both HCC-CCA and HCC; P = 1.00), tumor grade (42% grade 1-2 and 55% grade 3-4 for HCC-CCA versus 41% grade 1-2 and 58% grade 3-4 for HCC; P = 0.11), and degree of vascular invasion (50% microvascular invasion and 8% macrovascular invasion for both HCC-CCA and HCC; P = 0.99; Table 3 ). Comparison of recipient, donor, and operative characteristics among HCC-CCA and HCC patients matched on explant pathology demonstrates no significant differences with the exception of younger donor age in HCC-CCA (median 31 years versus 41 years; P = 0.02; Table 1 ). Similarly, there were no significant differences in the radiologic, biopsy, and treatment characteristic for recipients with HCC-CCA compared with those with HCC matched based on explant pathology ( Table 2 ). As expected given that matching was based on tumor pathologic characteristics, there were also no significant differences in explant pathologic characteristics between groups (Table 3) .
Posttransplant incidence of cancer recurrence, overall survival, and recurrence-free survival, when matching HCC-CCA to HCC patients on explant pathologic features, is shown in Fig. 5 . Compared with HCC recipients, HCC-CCA patients had slightly but not significantly greater 1-, 3-, and 5-year recurrence rates (16%, 50%, and 50% versus 7%, 22%, and 27%; P = 0.13; Fig. 5A ), and equivalent 1-, 3-, and 5-year overall (75%, 54%, and 42% versus 72%, 60%, and 48%; P = 0.54; Fig. 5B ) and recurrence-free survival (66%, 42%, and 42% versus 69%, 56%, and 44%; P = 0.44; Fig. 5C ).
ANALYSiS of RECiPiENtS WitH RECuRRENt HCC-CCA
Details of the tumor and treatment characteristics of each patient with HCC-CCA are shown in Table 4 .
Among the 6 patients with recurrent HCC-CCA, the median time to recurrence was 11.5 months (range 3-30 months) and median survival time was 22 months (range 5-58 months). Of the 6 patients with recurrent disease, 5 of them ultimately died from disease progression. The remaining patient was lost to follow-up after 23 months and is presumed dead because of disease. All 6 patients with recurrent disease demonstrated poorly differentiated tumors, and 4 of the 6 patients with post-LT recurrence demonstrated microvascular invasion. One NOTE: Data are given as % (n) or as median (interquartile range). * *P < 0.05 was considered significant. NOTE: Data are given as % (n) or as median (interquartile range). *P < 0.05 was considered significant. patient with poorly differentiated HCC-CCA and both microvascular and macrovascular invasion did not recur, dying at 5 months posttransplant as a result of an intravascular fungal infection. However, among the 5 patients with well or moderately differentiated tumors, there were no instances of HCC-CCA recurrence, with a median overall survival of 61 months (Fig. 5D) . A total of 4 patients were alive at last follow-up, and 1 died at 61 months following LT because of metastases from biopsy-proven primary lung cancer.
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Discussion
The surgical treatment of patients with primary liver malignancies including HCC, CCA, and HCC-CCA is challenging because of the frequent presence of prohibitive underlying liver fibrosis and cirrhosis that often prevents safe surgical resection. As a result, LT has unequivocally been established as the gold standard therapy for patients with unresectable HCC, with excellent longterm outcomes. (14) (15) (16) (17) (18) Similarly, LT is also an accepted therapy for not only unresectable hilar CCAs, with a 5-year recurrence-free survival of 65% in a recent multicenter study, (19) but is also now being considered for early stage intrahepatic CCAs based on the results of an international multicenter study. (20) Unfortunately, because of the inferior posttransplant outcomes observed in most series that evaluate patients with mixed HCC-CCA, (4) (5) (6) (10) (11) (12) 21, 22) LT has generally been contraindicated for patients carrying this diagnosis. The reasons for these poor outcomes have generally been felt to be due to aggressive tumor biology; however, data regarding the identification of HCC-CCA patients who may fare well with LT are limited. With this comparative, propensity-matched single-center analysis of 12 HCC-CCA patients undergoing LT, we show that while HCC-CCA patients are more likely to have poor tumor differentiation compared with HCC patients with similar pretransplant radiologic and AFP characteristics, they have similar outcomes to HCC patients when matched on explant pathologic characteristics, providing evidence that HCC-CCA tumors are not inherently more aggressive. Several single and multicenter studies have previously evaluated results of mixed HCC-CCA following LT (Table 5 ). One of the earliest studies from Mayo Clinic Jacksonville reported a 58% recurrence rate for HCC-CCA and a 5-year survival of 16%. (11) The group from Mount Sinai reported on 16 patients with HCC-CCA, with a post-LT recurrence of 44% and a 5-year survival of 48%. (21) More recently, single-center analyses from both China (22) and Korea (23) revealed post-LT recurrence rates of 52% and 38%, and 5-year survival of 39% and 66%, respectively. The best results have been reported from a multicenter Spanish study with recurrence in only 1 of 15 patients and a 5-year survival of 78%; (12) however, the overall rate of poorly differentiated tumors in this group of patients was only 8.8%, which included both HCC-CCA patients as well as iCCA recipients, making a granular determination of the particular favorable characteristics in this patient population difficult.
Because of the rarity of HCC-CCA, few studies are available to provide detailed evaluation of outcomes following LT. Although a few multicenter and database analyses (Table 5) have been previously published, the majority of these studies mix evaluation of intrahepatic cholangiocarcinoma and HCC-CCA. With only 213 cases of LT for HCC-CCA reported in the literature, the present series represents 5% of the previously reported cases, making the report of importance. Furthermore, larger scale database studies lack the depth to provide the extremely granular evaluation of tumor biology allowed by single-center analyses. To date, this is one of the largest single-center analyses of patients with mixed HCC-CCA. In addition, the study allows detailed comparison to patients with HCC through the propensity-matched analysis on both radiologic and explant pathologic factors, which to our knowledge has not been previously reported. One of the unique findings in our study relates to the 2 propensity-matched analyses we performed. While several previous studies have performed propensity matching to HCC controls based on pretransplant radiographic features or explant pathologic tumor size, (6, 12, 23) none of these other studies have matched based on tumor grade/differentiation, hence limiting the ability to address the question of whether HCC-CCAs are inherently more aggressive tumors. This limitation is highlighted by the fact that HCCCCAs have been shown to be significantly more likely to have poor differentiation compared with HCC. (24) Our study confirms that HCC-CCA patients are more likely to have poorly differentiated tumors compared with HCC controls matched on radiologic size and AFP. However, a unique and encouraging finding was that our HCC-CCA patients, when matched to HCC controls on explant pathologic features including tumor grade/differentiation, did not have inferior survival. In fact, while 6 of the 7 patients with poorly differentiated HCC-CCA developed recurrence, none of the 5 patients with well/moderate differentiation developed recurrence, with an excellent median survival of 61.4 months. Recurrent disease thus appears to be associated more with the tumor grade/differentiation than pathologic size or T stage ( identification of tumors at low risk for recurrent disease could make LT a potential therapeutic option for a subset of these patients. However, the challenge lies with accurately identifying these patients preoperatively. Radiographic imaging demonstrates poor sensitivity for lesions less than 2 cm. (25) Given the mixed component of the tumor, radiographic imaging may display either early, late, or both early and late enhancement on magnetic resonance imaging (MRI). (26) Panjala et al. performed a radiographic review of imaging from patients with HCC-CCA in order to determine particular radiographic characteristics of these tumors. They were unable to identify any imaging features or pattern of contrast uptake and washout that was pathognomonic for mixed HCC-CCA. (11) We retrospectively reviewed the radiographic descriptions of the tumors from all 12 patients, rereviewed the available imaging from 6 patients in our study group, and arrived at a similar conclusion. The majority of lesions in our study were diagnosed as HCC based on radiographic imaging; however, 7 nodules in 6 patients all demonstrated infiltrative margins without encapsulation, with a heterogeneous or mosaic pattern of enhancement noted in 6 of the 7 lesions (Fig. 3) . Identification of such radiographic findings not typical for HCC should alert the clinician of a potential alternative diagnosis such as HCC-CCA or iCCA.
Pretransplant pathologic diagnosis of HCC-CCA would be an alternative; however, biopsies are not routinely performed in many of these patients since pretransplant radiographic imaging is suggestive and often times diagnostic for HCC. Even in circumstances where the radiologic imaging features raise doubts about the certainty of the diagnosis, the reliability of pretransplant biopsy to make a definitive pathologic diagnosis of HCC-CCA has been poor. In the large multicenter Spanish cohort of 42 patients including both intrahepatic CCA (n = 27) and HCC-CCA (n = 15), 10 patients underwent pre-LT biopsy, with 7 biopsies incorrectly reporting a diagnosis of HCC and 3 biopsies being inconclusive. (12) Similarly, in the present study, only 33% of HCC-CCAs and 36% of HCCs were biopsied prior to transplant. Of the 4 HCC-CCA patients who underwent biopsy, 0 were diagnosed with mixed HCC-CCA; 2 were diagnosed as HCC, 1 with fibrolamellar HCC, and the fourth was diagnosed with poorly differentiated adenocarcinoma that was thought to likely represent HCC. In addition to this difficulty in securing the HCC-CCA diagnosis, a pre-LT assessment of tumor grade is equally unreliable. Of the 4 HCC-CCA patients who underwent pre-LT biopsy, 2 were diagnosed with a moderately differentiated tumor but proved to have a poorly differentiated HCC-CCA on final explant. These findings are in line with a recent large study of 234 HCC patients with a pre-LT biopsy of their tumors, which revealed poor sensitivity and specificity of a pre-LT biopsy in accurately identifying the tumor grade in the explant. (27) However, given the implications of a diagnosis of HCC-CCA, suspicion and judicious use of biopsy should be considered at any time that imaging findings deviate from expected. While there have certainly been advances in genetic sequencing and mutation analysis allowing for more selective identification of tumor pathology in primary hepatic malignancies, these diagnostic biomarkers are not currently widely used, and their sensitivity is not evaluated in the pretransplant setting. (28) Given that mixed HCC-CCA is considered a contraindication to LT by most centers, none of the patients in the present series bore a pretransplant diagnosis of mixed HCC-CCA. In our series, the patients who were transplanted within this study period did not routinely undergo adjuvant therapy following explant diagnosis of HCC-CCA. Systemic treatment was only initiated following recurrence of tumors in the subset of patients with poorly differentiated mixed tumors. However, it is possible that the routine use of adjuvant therapy in the posttransplant setting might decrease the risk of recurrence, and we have since changed our protocols to consider adjuvant systemic therapy in the subset of patients with mixed HCC/CCA where aggressive pathology is identified on explant (poor differentiation, vascular invasion). These higher risk HCC-CCAs will routinely receive adjuvant chemotherapy beginning within 3 months of LT.
There are several limitations to the present study. The first is that it is a retrospective, single-center analysis over a long time period. Variation in patient management and treatment is a potential bias for any retrospective study, and in this study, there were significant disparities in the pretransplant therapy of patients with HCC-CCA. In addition, the small sample size of the study group made performing a detailed statistical analysis difficult, potentially limiting the ability to identify factors that may be important in a better powered study. Despite these limitations, the strengths of our single-center analysis lie in the granularity of the radiologic and pathologic details impacting tumor recurrence and posttransplant survival, as well as the dual propensity-matched analyses, which have not been reported in any of the other single-center and registry studies.
In summary, we report one of the largest single-center experiences with LT for HCC-CCA. When matched to HCC controls based on pre-LT radiographic features and AFP, HCC-CCA recipients are more likely to have poorly differentiated tumors. However, when matched to HCC patients based on explant pathologic features, HCC-CCA patients have equivalent recurrence and survival outcomes, countering the contention that they are inherently more aggressive tumors. Perhaps most importantly, the subset of HCC-CCA with well to moderate tumor differentiation displayed excellent longterm survival without recurrence and represents a group of patients with HCC-CCA that is likely to derive longterm benefit from LT. Improvement in the preoperative identification of HCC-CCA patients with more discriminatory radiographic and pathologic biomarkers is necessary to allow for the adoption of LT as an effective therapy for patients with this rare malignancy.
